Nicotinamide Riboside (NR)
NAD+ precursor similar to NMN; more human trial data available. Raises NAD+ reliably.
Evidence last reviewed: 04 Apr 2026
- •those sensitive to niacin
- •individuals on antihypertensive medications
- •pregnant or breastfeeding women
Nicotinamide Riboside has moderate evidence showing consistent elevation of NAD+ levels and some cardioprotective signals in healthy and older adults. While no major adverse events have been reported, the clinical significance of potential risks remains unclear.
NAD+ levels / cardiovascular markersHealthy adults; older adults · RCTsModerate
Consistent NAD+ elevation; some cardioprotective signals; no major adverse events in trials to date.
Forms & usage▾
Take 250-300 mg daily, preferably in the morning with food.
Safety & trade-offs3▾
Nausea and flushing at higher doses
Context: doses >1000mg
Same theoretical NAD+-fuelled cell proliferation concern as NMN — clinical significance unknown
Modest blood pressure lowering — relevant for those on antihypertensives
●High ●Moderate ● Low / note